Ignite Creation Date:
2024-05-06 @ 7:21 PM
Last Modification Date:
2024-10-26 @ 3:05 PM
Study NCT ID:
NCT05983965
Status:
RECRUITING
Last Update Posted:
2024-05-08
First Post:
2023-08-01
Brief Title:
Study of Tazemetostat in Lymphoid Malignancies
Sponsor:
University of Alabama at Birmingham
Organization:
University of Alabama at Birmingham
Study Overview
Official Title:
Phase I Study to Evaluate Safety and Tolerability of Tazemetostat in Relapsedrefractory Peripheral T-cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Tazemetostat is an oral EZH2 inhibitor which has been FDA approved for adult patients with relapsed or refractory RR follicular lymphoma FL whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies and for adult patients with RR FL who have no satisfactory alternative treatment option We propose a study to evaluate the safety of tazemetostat in relapsed refractory peripheral T-cell lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None